https://orcid.org/0000-0001-6517-7948
References
- Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69–76.
- Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405–412.
- Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686–691.
- Yan TD, Stuart OA, Yoo D, et al. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med. 2006; 4:17.
- Karkouti K, Dattilo KM. Perioperative hemostasis and thrombosis. Can J Anaesth. 2006;53(12):1260–1262.
- Levy ML, Day JD, Fukushima T, et al. Surgicel Fibrillar absorbable oxidized regenerated cellulose. Neurosurgery. 1997;41(3):701–702.
- Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm. 2006;63(13):1244–1253.
- Amar A, Levy ML. Applications of topical hemostatic agents in neurosurgery. Contemp Surg Residents. 1996;4:19–22.
- Hutchinson RW, George K, Johns D, et al. Hemostatic efficacy and tissue reaction of oxidized regenerated cellulose hemostats. Cellulose. 2013; 20(1):537–545.
- Emilia M, Luca S, Francesca B, et al. Topical hemostatic agents in surgical practice. Transfus Apher Sci. 2011;45(3):305–311.
- Testini M, Marzaioli R, Lissidini G, et al. The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbecks Arch Surg. 2009;394(5):837–842.
- Bruckner BA, Blau LN, Rodriguez L, et al. Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures. J Cardiothorac Surg. 2014;9(1):134.
- Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–4567.
- Sugarbaker P. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.
- Mehta A, Mittal R, Chandrakumaran K, et al. Peritoneal involvement is more common than nodal involvement in patients with high-grade appendix tumors who are undergoing prophylactic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Dis Colon Rectum. 2017;60(11):1155–1161.
- Moran BJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf). 2006;28(4):375–378.
- Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy–a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14(8):2270–2280.
- Cavaliere F, Valle M, De Rosa B, et al. Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve. Suppl Tumori. 2005;4(3):S119–S121.
- Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56.
- Goodman MD, McPartland S, Detelich D, et al. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45–57.